Mirum(US:MIRM)2026-03-02 19:12Summary of Mirum Pharmaceuticals FY Conference Call Company Overview - Company: Mirum Pharmaceuticals (NasdaqGM:MIRM) - Focus: Building a leader in rare diseases by developing and commercializing best-in-class medicines [2][4] Financial Highlights - 2025 Revenue Guidance: Expected revenues between $630 million and $650 million [2] - 2026 Guidance: Strong performance anticipated, exceeding consensus estimates [4] Product Pipeline - Approved Medicines: Three approved medicines currently available [2] - Upcoming Trials: Four pivotal trials expected to unblind over the next 18 months, including: - PSC trial with volixibat in Q2 2026 - Interim analysis for Chenodal with 50 patients - AZURE-1 and AZURE-4 trials for Chenodal in the second half of 2026 - EXPAND trial with LIVMARLI for ultra-rare cholestatic indications [3] Commercial Performance - LIVMARLI Uptake: - Strong performance in Alagille syndrome with approximately 50% market penetration and an annual incidence of about 100 patients [4] - Achieving over 80% market share in Alagille [4] - Positive reception in PFIC, capturing at least 50% of treatment-naive patients [4][5] - Ex-US Market: Good visibility in major Western European countries, with growth expected in Alagille and PFIC [7] Expansion Opportunities - EXPAND Study: Initiated due to high demand from compassionate use requests; includes various ultra-rare indications [8] - Market Potential: Estimated peak sales for LIVMARLI could exceed $1 billion, with a third of sales from Alagille, PFIC, and the EXPAND population [10] Intellectual Property - Patent Expiration: Expected to extend to 2040 for dosing patents and 2043 for tablet patents [13] Volixibat Development - Target Population: Aimed at adults with PSC and PBC, with expectations for a clinically meaningful difference of at least 1.75 placebo-adjusted [15][20] - Interim Results: Positive interim results for PBC with significant pruritus benefits observed [21] Strategic Acquisitions - Bluejay Therapeutics: Acquired to enhance the hepatitis delta program, with a potential patient population of at least 15,000 diagnosed patients [31][33] Competitive Landscape - Hepatitis Delta Treatment: Brelovitug expected to have advantages in convenience and tolerability compared to competitors [35] - Market Dynamics: Anticipated increase in diagnosis rates with the introduction of new therapies [33] Future Outlook - Regulatory Submissions: NDA filing expected in the second half of 2026 following positive trial results [20] - Commercial Strategy: Plans to expand marketing efforts for volixibat and other therapies, focusing on community gastroenterologists and hepatologists [38] Conclusion - Growth Potential: Mirum Pharmaceuticals is positioned for significant growth in the rare disease market, with a robust pipeline and strategic acquisitions enhancing its portfolio [41]